陽普醫療(300030.SZ):一次性使用民用防護口罩獲得CE認證
格隆匯 9 月 7日丨陽普醫療(300030.SZ)公佈,近日,公司全資子公司陽普醫療(湖南)有限公司(“湖南陽普”)收到了由BSI(英國標準協會)頒發的CE認證證書,產品名稱:一次性使用民用防護口罩;證書編號:MODULEB(證書編號CE727788)、MODULEC2(證書編號CE727789);有效期:2020年9月3日至2021年9月3日。
上述產品取得CE認證證書,表明了湖南陽普生產的一次性使用民用防護口罩符合歐盟相關要求,已經具備歐盟市場的准入條件,將進一步提高公司在呼吸道防護領域的市場競爭力,對公司未來的經營將產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.